丹参多酚酸盐治疗心绞痛患者的临床研究

目的观察丹参多酚酸盐对心绞痛患者血脂、E选择素及炎性因子的影响。方法将我院心内科收治的106例心绞痛患者,随机分为试验组53例和对照组53例。对照组给予常规治疗;试验组在对照组基础上给予丹参多酚酸盐,每次250 mL,每天1次,静脉滴注。2组均治疗4周。比较2组患者的血脂、炎性指标、可溶性白细胞分化抗原40配体(sCD40L)、E-选择素、P-选择素、血小板聚集率及药物不良反应发生情况。结果治疗后,试验组患者5μmol·L-1腺苷二磷酸(ADP)诱导剂血小板聚集率、30μmol·L-1肾上腺素(EP)诱导剂血小板聚集率、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、sCD40L、E-选择素及P-选择素水平为(50.11±14.06)%,(27.14±16.51)%,(271.38±42.15)ng·L^-1,(390.58±104.47)μg·L^-1,(7.41±1.58)mg·L^-1,(3.75±1.03)mmol·L^-1,(1.85±0.61)mmol·L^-1,(3.24±0.82)mmol·L^-1,(1.75±0.64)mmol·L^-1,(8.27±2.41)μg·L^-1,(43.51±13.08)μg·L^-1,(223.74±39.17)μg·L^-1。对照组的上述指标分别为(63.28±10.17)%,(34.06±18.15)%,(310.75±59.37)ng·L^-1,(500.16±117.35)μg·L^-1,(9.12±2.76)mg·L^-1,(4.78±1.11)mmol·L^-1,(2.54±0.79)mmol·L^-1,(4.15±0.91)mmol·L^-1,(1.33±0.75)mmol·L^-1,(10.06±3.22)μg·L^-1,(53.34±14.58)μg·L^-1,(246.25±42.51)μg·L^-1,差异均有统计学意义(均P<0.05)。2组药物不良反应发生率比较,差异无统计学意义(P>0.05)。结论丹参多酚酸盐治疗心绞痛,可以有效降低患者炎性反应,并起到抗凝降脂的作用。

Clinical trial of salvianolate in the treatment of patients with angina pectoris

Objective To explore the effect of salvianolate on blood lipids, E selectin and inflammatory factors in patients with angina pectoris. Methods A total of 106 cases of patients with angina pectoris were randomly divided into treatment group(53 cases) and control group(53 cases). Control group was received routine treatment, treatment group was treated with salvianolate 250 mL on the basis of control group, intravous, once a day. All patients wre treated for 4 weeks. The blood lipids, inflammatory factors soluble CD40 ligand(sCD40 L), E-selectin, P-selectin, platelet aggregation rate and adverse drug reactions were compared between the two groups. Results After treatment, the 5 μmol·L-1 adenosine diphosphate(ADP) inducer platelet aggregation rate, 30 μmol·L-1 epinephrine(EP) inducer platelet aggregation rate,levels of interleukin 6( IL-6),tumor necrosis factor-α( TNF-α),hypersensitive C-reactive protein( hs-CRP),total cholesterol( TC),triglyceride( TG),low density lipoprotein cholesterol( LDL-C),high density lipoprotein cholesterol( HDL-C),s CD40 L,E-element and P-element in treatment group were( 50. 11 ± 14. 06) %,( 27. 14 ± 16. 51) %,( 271. 38 ± 42. 15) ng · L^-1,( 390. 58 ± 104. 47) μg · L^-1,( 7. 41 ± 1. 58) mg · L^-1,( 3. 75 ± 1. 03) mmol·L^-1,( 1. 85 ± 0. 61) mmol·L^-1,( 3. 24 ± 0. 82) mmol·L^-1,( 1. 75 ± 0. 64) mmol·L^-1,( 8. 27 ± 2. 41) μg·L^-1,( 43. 51 ± 13. 08) μg·L^-1,( 223. 74 ± 39. 17) μg·L^-1,all had significant difference with those in control group,which were( 63. 28 ± 10. 17) %,( 34. 06 ± 18. 15) %,( 310. 75 ± 59. 37) ng · L^-1,( 500. 16 ± 117. 35) μg·L^-1,( 9. 12 ± 2. 76) mg·L^-1,( 4. 78 ± 1. 11) mmol·L^-1,( 2. 54 ± 0. 79) mmol·L^-1,( 4. 15 ± 0. 91) mmol·L^-1,( 1. 33 ± 0. 75) mmol·L-1,( 10. 06 ± 3. 22) μg·L^-1,( 53. 34 ± 14. 58) μg·L^-1,( 246. 25 ± 42. 51) μg·L^-1( all P < 0. 05). There was no significant difference in the incidence of adverse drug reactions between the two groups( P > 0. 05). Conclusion The treatment of angina pectoris by salvianolate can effectively reduce the inflammatory reaction and play the role of anticoagulation and lipid lowering.